FindTrial
Sign In

Understanding Childhood CML: Insights on Stopping vs. Continuing Imatinib Treatment

A qualitative study of exploring and comparing the impact of discontinuation of tyrosine kinase inhibitors (TKI)/Imatinib vs continuing (TKI) Imatinib in childhood chronic myeloid leukemia (CML) patients: patients perspective - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/09/073667
Enrollment
50
Registered
2024-09-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G- Mental Health

Interventions

Intervention1: NIL: NIL Control Intervention1: NL: NIL

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • CML patients those who are continuing on TKI/ Imatinib, those patients in whom Imatinib is discontinued and patients whom discontinued and restarted on TKI/Imatinib • Age between 18-39 years and less than 15 years of age at the time of diagnosis • Marathi, Hindi and English speaking, able to undergo 30-40 minutes in depth interview

Exclusion criteria

Exclusion criteria: • Communication difficulty due to any cause or unable to give informed consent

Design outcomes

Primary

MeasureTime frame
Patients’ perspective about TKI discontinuationTimepoint: After 8 weeks from TKI discontinuation—

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable—

Countries

India

Contacts

Public ContactDr Nirmalya Roy Moulik

Tata Memorial Hospital

roymoulik@gmail.com7045991385

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026